When will AI biosecurity safeguards become U.S. law?

The core reason to lean No is that the evidence shows activity, not enactment. Multiple biosecurity- and AI-related proposals are circulating in Congress, but the most relevant items are still at the introduced or committee stage, which is a weak position this late in the session. For this market to resolve Yes, one of these measures would need to move quickly through committees, clear both chambers, and survive reconciliation or inclusion in a must-pass vehicle, all before the end of 2026. That is possible, but the procedural hurdles are substantial and the calendar is now the dominant constraint.

The best argument for Yes is that biosecurity is a narrower and more politically tractable slice of AI regulation than broader frontier-AI governance. There is visible support from some lawmakers, state attorneys general, and even industry voices, which increases the odds that at least one safeguard gets folded into a larger legislative package. If Congress were to attach biosecurity language to appropriations, defense, or authorization legislation, enactment could happen without a standalone AI bill. That path is credible enough to keep the probability above a token level.

Even so, the balance still favors No because support does not equal legislative throughput. The current proposals look fragmented, and the most prominent ones appear newly introduced or only partially developed, which leaves limited time for negotiation, scoring, committee markup, floor scheduling, and final passage. The market price of 27% is somewhat aggressive relative to that pipeline; I would expect a lower figure unless there is a sudden breakthrough into a must-pass bill. In other words, the market may be overweighting expressed support and underweighting the legislative bottleneck.